EAY191-S3
|
ECOG
|
EAY191-S3, Phase II Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors (A COMBOMATCH Treatment Trial)
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
EAZ171
|
ECOG-ACRIN
|
Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women
|
Cancer Prevention and Control CIRB
|
Available to Open
|
|
GOG-0198
|
GOG
|
A Randomized Study of Tamoxifen Versus Thalidomide (NSC # 66847) in Patients with Biochemical-Recurrence-Only Epithelial Ovarian Cancer; Cancer of the Fallopian Tube; and Primary Peritoneal Carcinoma after First Line Chemotherapy
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
GOG-0201
|
GOG
|
Treatment of Patients with Stage IB2 Carcinoma of the Cervix: A Randomized Comparison of Radical Hysterectomy and Tailored Chemoradiation VERSUS Primary Chemoradiation
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
GOG-0204
|
GOG
|
A Randomized Phase III Trial of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin in Stage IVB; Recurrent; or Persistent Carcinoma of the Cervix
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
GOG-0209
|
GOG
|
Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
GOG-0212
|
GOG
|
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or CT-2103 (IND# 70177) Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian; Primary Peritoneal; or Fallopian Tube Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
GOG-0213
|
GOG
|
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (Or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865; IND #113912) followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive; Recurrent Ovarian; Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865; IND #113912)(12/19/2011) (10/01/12) NCT# 00565851
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
GOG-0218
|
GOG
|
A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC #704865; IND #113912) Followed by Placebo; Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab; in Women With Newly Diagnosed; Previously Untreated; Stage III or IV; Epithelial Ovarian; Primary Peritoneal or Fallopian Tube Cancer
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
GOG-0219
|
GOG
|
A Phase III; Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2; IIA; IIB; IIIB; and IVA Cervical Carcinoma Limited to the Pelvis
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|